After a series of major exits from its C-suite last year and this year including the exit of Chief Medical Officer Andrew Cheng last fall, Gilead now has a new CMO as it also rejigs its R&D reporting line.
After snapping up Kite Pharma and moving more deeply into oncology, it’s little surprise that it has once again raided cancer specialist Roche/Genentech for its new CMO: Merdad Parsey, M.D., Ph.D., assumes the role at the start of next month, coming from his stint as senior vice president of early clinical development in the Genentech Research and Early Development (aka gRED) group.
While cancer was a focus for Parsey, other areas included inflammation and Gilead’s original focus, infectious diseases.
As part of the move, he will join the company’s senior leadership team and will report directly to Daniel O’Day, Gilead’s chairman and CEO and also a former Roche alum, having been its pharma chief.
But under a new structure, Gilead said William Lee, Ph.D., Gilead’s EVP of research, “will separately report to O’Day.”
Parsey also held the CEO role at 3-V Biosciences with previous stints at Sepracor, Regeneron and Merck, as well as at academic centers.
Just over a year ago, Andrew Cheng, M.D., Ph.D., left Gilead just six months after being appointed CMO. Cheng’s swift exit kept the revolving door spinning at the top of Gilead, which lost its CEO, CMO, CSO and executive chairman over a nine-month window.
John Martin, Ph.D., began the period of change by stepping down as executive chairman last March. The following month, Norbert Bischofberger, Ph.D., vacated the CSO chair. Then in July, John Milligan, Ph.D., furthered the turnover by revealing he will step down as CEO of Gilead at the end of the year after 28 years at the company.
In July of this year, and after nine years at Gilead and just over one year as CSO and R&D chief, John McHutchison, M.D., also said he was leaving the company. Robin Washington, the company’s longtime CFO, is also planning to retire next year.
“I am delighted to welcome Merdad, a seasoned and highly respected scientist, clinician and leader, to Gilead,” said O’Day. “Throughout his career, he has built a reputation as an outstanding leader among academic, industry and medical communities alike. I know Merdad’s exceptional skills and expertise will be of great benefit to Gilead as we focus on rapidly expanding our pipeline and clinical development portfolio through internal efforts and external partnerships.”
“I have had many opportunities over the course of my career to help shape clinical development strategies and programs, and I am profoundly excited to bring those experiences to Gilead, an organization I have long admired,” added Parsey.
“I am looking forward to working with the company’s talented teams to advance clinical development programs and build a robust pipeline that has the opportunity to change the trajectory of disease and transform the care of many more people in need around the world.”
By Ben Adams
Source: Fierce Biotech
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.